Your session is about to expire
← Back to Search
Dupilumab for Eosinophilic Gastrointestinal Diseases (ENGAGE Trial)
ENGAGE Trial Summary
This trial is researching an experimental drug to treat EoG & EoD, two uncommon, persistent, allergic/immune diseases, to reduce symptoms & inflammation in adults & adolescents.
ENGAGE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ENGAGE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My body weight is under 40 kg.I've had at least 2 episodes of gastrointestinal symptoms weekly in the last 8 weeks.I have previously participated in a dupilumab trial or have been treated with dupilumab.I am currently on tube feeding or IV nutrition.I am a teenager and my country allows me to join this study.I have been diagnosed with Helicobacter pylori infection.I have a narrow esophagus that can't be examined with a standard scope without dilation.I was diagnosed with Eosinophilic gastritis through a biopsy at least 3 months ago.I do not have conditions like Churg-Strauss syndrome or hyper-eosinophilic syndrome.I am expecting to undergo a major surgery during the study.My symptom scores have been high for the past 2 weeks.I have a history of specific digestive conditions or surgeries.My biopsy shows I have EoG due to high eosinophil levels.
- Group 1: Part B: Phase 3
- Group 2: Part C: Extended Active Treatment Period
- Group 3: Part A: Phase 2
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical research recruiting participants at present?
"Affirmative. The latest information from clinicaltrials.gov specifies that this research initiative, which began on May 3rd 2023, is currently enrolling patients. A total of 279 participants are needed between two medical centres."
How many individuals are partaking in the current clinical trial?
"Affirmative. According to information on clinicaltrials.gov, this therapeutic experiment is currently signing up participants and was last updated on May 12th 2023. The trial requires 279 individuals from 2 medical facilities to be recruited."
To what end is this trial aiming to reach?
"The principal aim of this trial, to be monitored at Week 24, is the alteration in the Eosinophilic Gastritis/Eosinophilic Duodenitis Symptom Questionnaire (EoG/EoD-SQ) Total Symptom Score (TSS). Secondary objectives include measuring changes in peak gastric tissue eosinophil count and peak duodenal tissue eosinophil count across Part A, B, and C for those with duodenal involvement. Lastly, researchers will gauge how many participants achieved a peak duodenal tissue eosinoph"
Share this study with friends
Copy Link
Messenger